BACKGROUND: Black women with endometrial cancer are more likely to die of their disease compared with white women with endometrial cancer. These survival disparities persist even when disproportionately worse tumor characteristics among black women are accounted. Receipt of less complete adjuvant treatment among black patients with endometrial cancer could contribute to this disparity. OBJECTIVE: We assessed the hypothesis that black women with endometrial cancer are less likely than their white counterparts to receive adjuvant treatment within subgroups defined by tumor characteristics in the NRG Oncology/Gynecology Oncology Group 210 Study. STUDY DESIGN: Our analysis included 615 black and 4283 white women with endometrial cancer who underwent hysterectomy. Women completed a questionnaire that assessed race and endometrial cancer risk factors. Tumor characteristics were available from pathology reports and central review. We categorized women as low-, intermediate-, or high-risk based on the European Society for Medical Oncology definition. Adjuvant treatment was documented during postoperative visits and was categorized as no adjuvant treatment (54.3%), radiotherapy only (16.5%), chemotherapy only (15.2%), and radiotherapy plus chemotherapy (14.0%). We used polytomous logistic regression to estimate odds ratios and 95% confidence intervals for multivariable-adjusted associations between race and adjuvant treatment in the overall study population and stratified by tumor subtype, stage, or European Society for Medical Oncology risk category.
RESULTS:
Overall, black women were more likely to have received chemotherapy only (odds ratio, 1.40; 95% confidence interval, 1.04e1.86) or radiotherapy plus chemotherapy (odds ratio, 2.01; 95% confidence interval, 1.54e2.62) compared with white women in multivariable-adjusted models. No racial difference in the receipt of radiotherapy only was observed. In tumor subtype-stratified models, black women had higher odds of receiving radiotherapy plus chemotherapy than white women when diagnosed with low-grade endometrioid (odds ratio, 2.04; 95% confidence interval, 1.06e3.93) or serous tumors (odds ratio, 1.81; 95% confidence interval, 1.07e3.08). Race was not associated with adjuvant treatment among women who had been diagnosed with other tumor subtypes. In stage-stratified models, we observed no racial differences in the receipt of adjuvant treatment. In models that were stratified by European Society for Medical Oncology risk group, black women with high-risk cancer were more likely to receive radiotherapy plus chemotherapy compared with white women (odds ratio, 1.41; 95% confidence interval, 1.03e1.94). CONCLUSION: Contrary to our hypothesis, we observed higher odds of specific adjuvant treatment regimens among black women as compared with white women within specific subgroups of endometrial cancer characteristics.
Key words: adjuvant treatment, endometrial cancer, racial differences, tumor heterogeneity E ndometrial cancer (EC) is the fourth most common cancer among women in the United States, with 63,230 new cases expected in 2018. 1 Racial disparities in EC mortality rates are well-documented, with black women with EC experiencing a 93% higher death rate compared with white women with EC. This represents one of the largest racial disparities in mortality rates among common cancers. 2 Although black women more commonly exhibit aggressive tumor characteristics (eg, nonendometrioid subtypes and advanced stage disease) 3e7 that contributes to their worse prognosis, 8 racial differences in survival within these subgroups are apparent. For example, in an analysis that was restricted to patients with EC with advanced stage or recurrent disease, Maxwell et al 9 reported significantly worse survival among black women as compared with white women. In a study of patients with EC with stage I or II disease who were <50 years old, black women had a 24% higher risk of death than white women. 10 Apart from a higher prevalence of aggressive tumor characteristics, 11 other factors that include lower socioeconomic status, 12 presence of comorbidities, 13 and the receipt of less complete treatment among black patients with EC could contribute to racial disparities in EC survival. 14 Most patients with EC begin treatment with hysterectomy, bilateral salpingo-oophorectomy, and lymph node sampling. 15 After surgery, adjuvant treatment is recommended on the basis of tumor characteristics that are determined at the time of hysterectomy.
Poor tumor differentiation, nonendometrioid histologic findings, and tumors with invasion into the myometrial wall are clinical indications for adjuvant treatment with radiotherapy and/or chemotherapy. As mentioned, these aggressive tumor features are more common among black women; therefore, observations that black women with EC more commonly receive adjuvant treatment than white women with EC are expected. 12,17e20 Still, others report no difference in the receipt of adjuvant treatment between black and white patients with EC. 19,21e23 An important limitation of studies that use hospital registry data is the ascertainment of adjuvant treatment. Although details of hospital-based treatments that include surgery and to a lesser extent radiotherapy are collected reliably, 24, 25 systemic treatments typically are delivered in outpatient settings and are more susceptible to measurement error. We undertook the current analysis to clarify associations between race and the receipt of specific adjuvant treatment regimens according to tumor characteristics that guide treatment assignment. This information will be useful to clinicians who treat diverse populations of patients with EC. Based on poorer survival among black patients with EC within subgroups defined by tumor characteristics, we hypothesized that the receipt of adjuvant treatment would be lower among black patients compared with white patients within subgroups defined by tumor features in the large NRG Oncology/Gynecologic Oncology Group (GOG) 210 study.
Materials and Methods
The NRG Oncology/GOG 210 Study was conducted from September 22, 2003 , to December 1, 2011, at 62 US institutions. Eligible patients included women with presurgical diagnoses of EC or carcinosarcoma who were eligible for surgery and had not undergone previous retroperitoneal surgery or pelvic/abdominal radiation. Before surgery (hysterectomy, bilateral salpingo-oophorectomy, and lymph node sampling at the discretion of the treating provider), consenting patients completed a self-administered questionnaire that collected demographic and risk factor information. 4 On September 23, 2007, eligibility criteria in NRG Oncology/GOG 210 changed from unrestricted enrollment to restricted enrollment of poor prognosis cancers (eg, nonendometrioid) and cancers that occur among nonobese and nonwhite patients.
Of 6124 women enrolled, 632 women (10%) did not complete questionnaires and were excluded from further analyses. We excluded women for the following reasons: incomplete surgical staging (n¼20), final diagnosis not EC (n¼53), benign diagnoses (n¼6), diagnosis of a second primary (n¼2), misclassified pathologic diagnosis based on central pathologic review (n¼49), inadequate material for pathologic review (n¼22), protocol deviations (n¼17), and improper preprotocol treatment (n¼1). We excluded women with missing grade (n¼23), mucinous tumors (n¼18), unusual histologic types (which included squamous cell, undifferentiated, and dedifferentiated histologic data; n¼111), missing stage (n¼5), self-reported race other than black or white (n¼231), and unknown adjuvant treatment status (n¼36), which left 4898 patients for analysis. This study was approved by Institutional Review Boards at the National Cancer Institute and participating study centers. All participants provided informed, written consent before participation.
Questionnaires assessed information on demographic characteristics (age, race, annual income, highest level education attained) and established EC risk factors that included height, weight, reproductive factors, diabetes mellitus, smoking status, oral contraceptive use, menopausal hormone use, tamoxifen use, and history of breast cancer.
Pathologic information was available from participating NRG Oncology/GOG institutions and through specialized reviews 4 that were performed by the NRG Oncology/GOG Pathology Committee. Specifically, diagnoses of high-grade endometrioid carcinoma, serous carcinoma, clear cell carcinoma, carcinosarcoma, and tumors that involved the cervix or with nonnodal metastases were reviewed by a panel of gynecologic pathologists. Endometrial tumor subtypes were classified as low-grade (grades 1 and 2) endometrioid carcinoma (n¼2614), high-grade (grade 3) endometrioid carcinoma (n¼593), serous carcinoma (n¼677), mixed epithelial (n¼536), carcinosarcoma (n¼312), or clear cell carcinoma (n¼166). Depth of myometrial invasion (negative, inner half, outer half, serosal involvement), stage according to International Federation for Gynecology and Obstetrics 1988 criteria, 26 pelvic and/or aortic lymph node involvement, peritoneal cytologic and biopsy results, and extrauterine sites AJOG at a Glance Why was this study conducted? This study was conducted to assess the hypothesis that black women with endometrial cancer are less likely than their white counterparts to receive adjuvant treatment in models stratified by tumor characteristics.
What are the key findings?
In histologically stratified models, black women with low-grade endometrioid or serous tumors were more likely to receive chemotherapy only or radiotherapy plus chemotherapy compared with white women. In models that were stratified by the European Society for Medical Oncology definition of risk, black women with high-risk cancer were more likely to receive radiotherapy plus chemotherapy compared with white women.
What does this add to what is already known?
Our focus on specific types of adjuvant treatment regimens along with subgroup analyses provides greater clarity in understanding racial differences in the receipt of adjuvant treatment.
Original Research GYNECOLOGY ajog.org After the postsurgical clinic visit, which occurred approximately 6 weeks after surgery, patients were observed every 3 months for the first 2 years, every 6 months for the next 3 years, and then annually for the next 5 years. All cancerrelated adjuvant treatment was documented prospectively on standard follow-up forms. Treatment decisions were made by the treating clinician. We categorized adjuvant treatment as no adjuvant treatment, radiotherapy only, chemotherapy only, or radiotherapy plus chemotherapy. Detailed information on treatment (eg, radiotherapy type, radiotherapy dose, chemotherapy agents, chemotherapy dose) was unavailable.
Tumor and treatment characteristics were compared between black and white women with EC with the use of chisquare tests. We used unordered polytomous logistic regression to estimate odds ratios (ORs) and 95% confidence intervals (CIs) for associations between race and the receipt of adjuvant treatment, with no adjuvant treatment as the reference. We first examined an overall model with minimal adjustment for age at diagnosis, tumor subtype, stage, annual income, and educational attainment. Missing values for income and educational attainment were modeled as separate categories. We considered the epidemiologic characteristics listed in Table 1 as potential confounders by adding them to the minimally adjusted models. Because inclusion of these factors did not change minimally adjusted estimates for the association between race and the receipt of adjuvant treatment by >10%, no additional adjustments were made. We also examined the same polytomous logistic regression model stratified by tumor subtype, stage, or European Society for Medical Oncology (ESMO) risk category. The ESMO classifier includes 3 groups (low-, intermediate-, or high-risk) based on stage (including depth of myometrial invasion) grade, and histologic findings. 28 This classifier was selected because it does not incorporate lymphovascular space invasion and we lacked information on this variable. Because the high-risk category includes a heterogeneous group (all stages with nonendometrioid histologic findings), we adjusted this model for stage and tumor subtype. ajog.org
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When we observed significant differences in the receipt of adjuvant therapy in stratified models, we compared distributions of other tumor characteristics (eg, peritoneal cytologic findings, peritoneal metastasis, aortic lymph node involvement, and pelvic lymph node involvement) between black and white women within those strata to determine whether these factors contributed to racial differences in the receipt of adjuvant therapy. Statistical analyses were performed with SAS software (version 9.3; SAS Institute, Cary, NC). All probability values were 2-sided; statistical significance was set at P<.05.
Results
Of the 4898 study participants, 12% (n¼615) self-reported black race. Table 1 shows distributions of epidemiologic characteristics according to race. Compared with white women with EC, black women with EC were more likely to have less than high school education, have lower annual incomes, be nonusers of menopausal hormones, be obese, have more live births, and have a history of diabetes mellitus. Distributions of tumor and treatment characteristics among black and white women with EC are shown in Table 2 . Compared with white women with EC, black women with EC had a higher prevalence of aggressive tumor characteristics, which included positive pelvic and/or aortic lymph node involvement, positive peritoneal cytologic findings, advanced stage, tumor subtypes other than low-grade endometrioid, highrisk tumors as defined by ESMO, and a lower prevalence of complete surgical staging. Adjuvant chemotherapy only and radiotherapy-plus chemotherapy regimens were more common among black than white women.
Overall, more than one-half of women with EC received no adjuvant treatment (54.3%); 16.5% of the women received radiotherapy only; 15.2% of the women received chemotherapy only, and 14% of the women received radiotherapy plus chemotherapy. Figure 1 shows multivariable-adjusted associations between race and the receipt of adjuvant treatment overall and stratified by tumor subtype. In the overall model, black women were more likely to receive chemotherapy only (OR, 1.40; 95% CI, 1.04e1.86) or radiotherapy plus chemotherapy (OR, 2.01; 95% CI, 1.54e2.62) compared with white women. Race was not associated with the receipt of radiotherapy only compared with no adjuvant treatment. In analyses that were stratified by tumor subtype, we noted racial differences in the receipt of radiotherapy plus chemotherapy among women who had been diagnosed with low-grade endometrioid tumors (OR, 2.04; 95% CI, 1.06e3.93) or serous tumors (OR, 1.81; 95% CI, 1.07e3.08). No racial differences in the receipt of radiotherapy only or chemotherapy only regimens were observed in the tumor subtype-stratified models.
We also explored distributions of other tumor characteristics (eg, peritoneal cytologic findings, aortic lymph node involvement) among white and black women with low-grade endometrioid or serous tumors. Among women with low-grade endometrioid tumors, we observed a higher proportion of invasion into the outer half of the myometrium among white compared with black women (18.3% vs 12.7%). We observed no racial differences in prevalence of tumor characteristics among women with serous tumors. Complete surgical staging did not vary between black and white patients with EC within these strata.
We observed no differences in the receipt of adjuvant treatment according to race in models that were stratified by stage (Figure 2 ). In models that were stratified by ESMO risk category (Figure 3) , no racial differences in the receipt of adjuvant treatment were Original Research GYNECOLOGY ajog.org noted for women in the low-or intermediate-risk groups; however, among women in the high-risk category, we observed higher odds of the receipt of radiotherapy plus chemotherapy among black as compared with white patients with EC (OR, 1.41; 95% CI, 1.03e1.94). In this stratum, no racial differences in the receipt of radiotherapy only or chemotherapy only regimens were observed. Aortic lymph node involvement was significantly more common among black than white patients with EC in the high-risk group (17% vs 13%; P¼.002).
Comment
On the whole, studies that evaluate survival after a cancer diagnosis demonstrate lower survival rates among black women compared with white women. 29 Morris et al 30 describe several mechanisms that likely contribute to this observation: aggressive clinical characteristics, lower socioeconomic status, higher prevalence of comorbid conditions, poor patient-provider interactions, and inferior treatment. In this large cohort of women with EC, we examined the receipt of specific adjuvant treatments among black and white women in the overall study population and according to tumor characteristics that guide treatment recommendations. Contrary to our hypothesis, we observed that black women had higher odds of receiving certain adjuvant treatment regimens, which varied according to tumor subtype and ESMO risk category. The association between race and adjuvant treatment in the NRG Oncology/Gynecologic Oncology Group 210 Study, overall and stratified by tumor subtype Data show that black women were more likely to receive chemotherapy only or radiotherapy plus chemotherapy compared with white women in the overall study population. The tumor subtypeestratified models showed racial differences in the receipt of radiotherapy plus chemotherapy among women who were diagnosed with low-grade endometrioid tumors or serous tumors.
CI, confidence interval; CT, chemotherapy; OR, odds ratio; RT, radiotherapy. ajog.org
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We noted that black women had higher odds of the receipt of chemotherapy only or radiotherapy plus chemotherapy compared with white women. Our large study population with a central review of tumor characteristics also provided an opportunity to explore in-depth whether the association between race and the receipt of specific adjuvant treatment regimens varied within categories defined by tumor characteristics, which is a notable extension of the previous literature. We noted some racial differences in the receipt of adjuvant treatment; radiotherapy plus chemotherapy was more common among black women who had been diagnosed with low-grade endometrioid EC or serous EC. In addition, among women with high-risk EC, we noted higher odds of receiving radiotherapy plus chemotherapy among black women. No racial differences in the receipt of adjuvant treatment were observed in models that were stratified by stage alone, which is in contrast to a National Cancer Database analysis in which black women with advanced stage disease had 12% higher odds of receiving adjuvant treatment compared with similarly staged white women with EC. 20 Our findings are distinct from previous studies that reported no racial differences in the receipt of adjuvant treatment. 19,21e23 Findings from our study and the National Cancer Database analysis might reflect that other factors, including overall health of the patient and treatment preference, also guide a clinician's decision to provide adjuvant treatment, which are factors that were unaccounted for in the respective The association between race and adjuvant treatment in the NRG Oncology/Gynecologic Oncology Group 210 Study stratified by stage Data show no racial differences in the receipt of adjuvant treatment in models stratified by stage.
CI, confidence interval; CT, chemotherapy; OR, odds ratio; RT, radiotherapy. Original Research GYNECOLOGY ajog.org analyses. Moreover, we speculate that these unanticipated findings may be attributable partially to increased clinician awareness of poorer survival among black as compared with white patients with EC, which may have motivated more intense treatment in the absence of clinical indications. Over the past two decades, several reviews that have described the survival disparity among black and white patients with EC have been published, 31e33 which prompted national attention to this problem.
The National Comprehensive Cancer Network guidelines warrant adjuvant radiotherapy plus chemotherapy for women with low-grade endometrioid tumors when the tumor invades into the serosa or beyond (stage IIIA or higher).
16
Although black patients with EC have a higher prevalence of advanced stage disease than white patients with EC, our tumor subtypeestratified analyses were adjusted for stage. Our finding of the increased use of radiotherapy plus chemotherapy among black women with low-grade endometrioid EC suggests that clinicians are potentially over prescribing this treatment. This pattern of over treatment could contribute to the deleterious survival outcomes that have been observed among black women. On the other hand, adjuvant treatment with any combination of radiotherapy and/or chemotherapy is indicated among women with serous tumors, regardless of stage. Because survival from serous EC is poor for all women, regardless of race, it is unclear what additional factors might lead to the increased use of radiotherapy plus chemotherapy among black women with this aggressive subtype. We did not observe a higher prevalence of other aggressive tumor characteristics among black women with low-grade endometrioid or serous tumors that would explain our observations. In the highrisk ESMO group, we did note that The association between race and adjuvant treatment in the NRG Oncology/Gynecologic Oncology Group 210 Study, stratified by European Society for Medical Oncology risk group Data show that black women were more likely to receive radiotherapy plus chemotherapy compared with white women in the subgroup of women with high-risk endometrial cancer.
CI, confidence interval; CT, chemotherapy; OR, odds ratio; RT, radiotherapy. ajog.org GYNECOLOGY Original Research black women had greater involvement of the aortic lymph nodes, possibly contributing to increased use of radiotherapy plus chemotherapy.
Our data are limited in their ability to provide explanations for the intriguing observations noted in this study population. Additional hypotheses of interest that we cannot address directly with these data include the possibility of racial differences in treatment preference/adherence, quality of patient-provider communications, and regional variations in treatment patterns. This last point may be particularly relevant in our study, given the national recruitment for this study. In the National Cancer Database analysis, striking regional differences in prescribing EC adjuvant treatment were observed; patients from the Northeast, Midwest, Great Lakes, and Atlantic regions had higher odds of receiving adjuvant treatment compared with patients in the South. 20 Because the racial distribution of patients with EC differs by region, there is likely an important interaction between geographic residence and race that could impact treatment receipt. In this secondary data analysis, we lack information on patient residence and cannot address this hypothesis directly with our data.
Despite unclear mechanisms that link race with adjuvant treatment receipt, it is apparent that black women with EC continue to experience worse outcomes than their white counterparts. 20, 34 In our NRG Oncology/GOG 210 Study population, black patients with EC have significantly higher risks of all-cause mortality rates (hazard ratio, 1.21), ECspecific mortality rates (hazard ratio, 1.27), and recurrence risk (hazard ratio, 1.36). 34 These outcomes are independent of tumor characteristics, socioeconomic factors, and treatment. That the survival metrics for black patients with EC have somewhat improved over the past two decades suggests progress; 18, 20 however, the persistent gap in survival for black women should be addressed with additional prospectively designed research. Moreover, research on other minority groups clearly is needed.
Our study has several strengths that include the prospective design, long follow-up period, large sample size, and prospective collection of adjuvant treatment information. This last feature limits the extent to which our results are explained by differential misclassification of treatment between black and white patients. Like previous studies, we were unable to examine associations among women of other racial minority groups, whom we excluded from this analysis because of extremely small sample sizes. We also lacked data on the type of radiotherapy (eg, brachytherapy, external beam, combination), which would have allowed for an assessment of whether women received treatment in line with National Comprehensive Cancer Network recommendations.
Finally, women enrolled in this study were treated at academic specialty centers, which limited our ability to generalize to women treated in community settings. Nonetheless, this case-series is one of the largest and includes a diverse group of well-characterized endometrial tumors among black and white women with centrally reviewed tumors, availability of epidemiologic risk factor information, and prospectively collected treatment data.
In summary, we observed that black women with EC had higher odds of receiving certain adjuvant treatment regimens compared with white women. In the setting of low-grade, early-stage disease, this may represent over prescription, potentially because of clinician concerns about racial disparities in EC survival. Prospective studies that will focus on contextual patient-level factors, patient-provider interactions, and treatment facility characteristics are warranted to increase our understanding of adjuvant treatment receipt in EC. n
